Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VEEV · Q2 2026 Earnings

Veeva Systems

Reported August 27, 2025

30-second summary

Veeva delivered Q2 FY2026 revenue of $789M (+17% YoY) and non-GAAP EPS of $1.99, beating its own prior guide by ~3% on revenue and ~5% on EPS, and raised FY26 guidance across revenue (+$42M midpoint), non-GAAP EPS (+$0.15 to $7.78), and non-GAAP operating income (+$28M to ~$1,388M). The substantive change this quarter is the IQVIA settlement removing data-and-analytics constraints on Nitro and Network — management's language shifted from "stymied" to "the runway is clear" — alongside Vault CRM crossing 100 live customers with 7 of the top 20 biopharmas now committed.

Headline numbers

EPS

Q2 FY2026

$1.99

Revenue

Q2 FY2026

$0.79B

+17.0% YoY

Gross margin

Q2 FY2026

75.3%

Operating margin

Q2 FY2026

24.8%

Key financials

Q2 FY2026

Metric	Q2 FY2026	YoY	Q1 FY2026	QoQ
Revenue	$0.79B	+17.0%	$0.76B	+4.0%
EPS	$1.99	—	$1.97	+1.0%
Gross margin	75.3%	—	77.1%	-180bps
Operating margin	24.8%	—	30.8%	-600bps

Guidance

Veeva beat Q2 FY2026 guidance on revenue and EPS and raised full-year FY2026 guidance across revenue, EPS, and operating income; strong execution and pipeline firming driving upward momentum.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q2 FY2026	$766–$769 million	$789 million	+$20–$23 million above guide	Beat
Non-GAAP EPS	Q2 FY2026	$1.89–$1.90	$1.99	+$0.09 above guide	Beat
Non-GAAP Operating Income	Q2 FY2026	$335–$337 million	$352.8 million	+$15.8–$17.8 million above guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	Q3 FY2026	$790–$793 million	—
Non-GAAP EPS	Q3 FY2026	$1.94–$1.95	—
Non-GAAP Operating Income	Q3 FY2026	$348–$350 million	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$3,090–$3,100 million	$3,134–$3,140 million	+$34–$50 million	Raised
Non-GAAP EPS	FY2026	$7.63	$7.78	+$0.15	Raised
Non-GAAP Operating Income	FY2026	about $1,360 million	about $1,388 million	+$28 million	Raised

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
Veeva Commercial Solutions - Subscription Services	$0.308B	+13.1%
Veeva R&D Solutions - Subscription Services	$0.352B	+21.5%
Veeva Commercial Solutions - Professional Services and Other	$0.048B	+5.9%
Veeva R&D Solutions - Professional Services and Other	$0.082B	+17.7%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026
Subscription Services Revenue	$659.2M
Subscription Services YoY Growth	17%
Gross Margin (GAAP)	75.3%
Non-GAAP Gross Margin	77.5%
Operating Margin (GAAP)	24.8%
Non-GAAP Operating Margin	44.7%
Vault CRM Live Customers	100+
Top 20 Biopharmas with Veeva eTMF	20 of 20

Management tone

Narrative arc: Q1 "AI as operating model" → Q2 "IQVIA constraint released, runway clear."

IQVIA shifted from competitive constraint to unlocked roadmap, and the language is unusually direct. For multiple quarters Nitro and Network — Veeva's data and analytics products — were described as constrained by the IQVIA dispute. This quarter management framed it as resolved: "For the ones that dealt with data and analytics, those were stymied due to the IQV restrictions. So long story short… The runway is clear. You know, we just have to do that hard work to go down that path." The signal is that the next phase of Commercial Cloud growth depends on execution rather than litigation overhang, which structurally changes the risk profile of the data-and-analytics roadmap.

Vault CRM moved from "structural advantage on paper" to "structural advantage with two top-20 references live." Last quarter Vault CRM was 80+ customers and management was making the case that Salesforce's life sciences cloud deprecation would force migration. This quarter the framing is proof-based: "With Viva, a win almost becomes a certainty. We have to work at it. I don't want to make it sound too easy, but these are two significant live and happy customers now in some of their major markets." The Salesforce competitive timeline was simultaneously pushed out — management characterized the earliest top-20 Salesforce go-live as end-2026 finishing potentially in 2029, with "low chance" all three commits go live in all regions. That's a more aggressive read on the competitor than prior quarters.

AI shifted from product roadmap to "AI projects are business consulting projects." Q1 framed Veeva AI through a directional 4:1 value claim. Q2 reframed the go-to-market: "Every AI project is a business consulting project because you're changing the boundaries of what the humans do and what the agents do." This is operationally significant — it positions Veeva's business consulting arm as a leading indicator for AI revenue, and admits that AI adoption requires organizational change, not just software. The December 2025 first release is still on track, with an expanded 2026 roadmap (clinical, regulatory, safety, quality, medical agents).

Pipeline visibility firmed. Q1 carried explicit macro caution ("more uncertain than 90 days ago"). Q2 inverted that posture: Q3 and Q4 are "closer now than 90 days ago with things firming up in pipeline." The FY raise being larger than the Q2 beat is consistent with that — management is leaning into visibility rather than de-risking it.

One area of restraint: Compass and AI early adopters. Management flagged that Compass (prescriber data) is facing "resistance to change" and slower ramp than expected, and that AI early adopters wanted to start "even far before the software was ready." This is unusually honest framing on a print where everything else accelerated, and worth noting in a quarter where the temptation would be to claim universal momentum.

Recurring themes management leaned on this quarter:

IQVIA settlement removes data/analytics product constraintsVault CRM go-lives proving superiority vs. Salesforce timeline riskAI agents embedded in deep applications as structural advantageCross-X audiences business driving commercial growth momentumMigration machine ramping 2026-2027 with 300+ customers remainingBusiness consulting as leading indicator for AI transformation projects

Risks management surfaced:

Compass prescriber product facing resistance to change, slower ramp than expectedAgentic AI requiring business consulting—not just software—to drive adoptionSalesforce top 20 verbal commits carry contingency plan risk through 2029Migration execution required at scale across 300+ Viva CRM customersMacro uncertainty remains elevated, though stable

Answers to last quarter's watch list

Vault CRM live customer count — 100+ live customers (up from 80+), with 7 of the top 20 biopharmas now committed and two top-20s live in major markets. The cadence accelerated and management explicitly named two top-20 live references — the gating event for the 2027 Salesforce deprecation deadline. Status: Resolved positively

Commercial Solutions services revenue — Swung from -4.5% YoY in Q1 to +5.9% in Q2 at $48M. The self-sufficiency narrative is harder to maintain; implementation revenue is back. Whether this is durable migration-driven services demand or one-quarter lumpiness needs another print to call. Status: Continue monitoring

Crossix usage-based revenue disclosure — Not called out on the print. Commercial subscription growth held at +13.1% versus +16.9% last quarter, which is consistent with the Crossix usage-based lumpiness flagged in Q1 reversing somewhat, but the company didn't disclose a specific Crossix figure or growth rate. Status: Continue monitoring

Veeva AI December launch specifics — December 2025 release reaffirmed for CRM and commercial content, with clinical, regulatory, safety, quality, medical and commercial planning agents added to the 2026 roadmap. No pricing model or named early-access customers disclosed, though management acknowledged one early adopter "wanted to get going even far before the software was ready." Status: Continue monitoring

Horizontal CRM first-customer announcement — Not addressed in the disclosed materials this quarter. The Q3 print becomes the credibility checkpoint. Status: Not resolved

Small biotech pipeline commentary — Reversed cleanly. Management characterized Q3 and Q4 as "closer than 90 days ago with things firming up in pipeline," and described "broad-based strength." The Q1 macro caution did not flow through to 2H. Status: Resolved positively

What to watch into next quarter

Nitro and Network revenue or customer disclosure — Now that IQVIA restrictions are removed, watch for any quantified ramp on data-and-analytics products. Management said customer reaction is "overwhelmingly positive"; the next print should show that in either a named customer count or segment commentary.

Top-20 Vault CRM commits beyond 7 — Currently 7 of top 20 committed and 2 live. Hitting 10+ committed by Q3 would put the 2027 Salesforce deprecation timeline in Veeva's favor; staying at 7 would suggest top-20 sales cycles are longer than the 100+ aggregate number implies.

Commercial services revenue trajectory — Watch whether the +5.9% Q2 print extends or reverses. Sustained mid-single-digit services growth alongside Vault CRM ramp validates the multi-product land thesis; a reversion to negative would mean Q2 was implementation lumpiness.

Veeva AI December launch deliverables — Pricing, named early-access customers, and which of the 2026-roadmap agents (clinical, regulatory, safety, quality, medical) have committed pilots. The "AI projects are business consulting projects" framing is testable — if Veeva discloses any business consulting bookings tied to AI, that's the early monetization signal.

Horizontal CRM first customer — Gassner committed in Q1 to first customers by year-end. Q3 is the natural checkpoint; absence of names by then would be a credibility issue.

Compass prescriber product — Management explicitly flagged slower ramp and resistance to change. Watch whether Q3 commentary cites improvement, continued drag, or quiet reframing.

Sources

Veeva Systems Q2 FY2026 press release, SEC filing (veev-20250731q226xex991.htm), August 27, 2025.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.